World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 


UNITAID Invests To Increase Access To Malaria Treatment

UNITAID Invests To Increase Access To Severe Malaria Treatment

Geneva – 11 April 2014. UNITAID is dedicating 34 million USD on reducing malaria case-fatality through its project rolling out over the coming weeks to treat the severest cases. Every year thousands of children across Africa die from severe malaria. If left untreated, severe malaria leads to almost certain death within 48 hours. In 2012, malaria killed an estimated 483,000 children under-five years of age. UNITAID’s new investment in six high malaria burden countries is estimated to cut malaria case-fatality rates by more than 10%.

In health facility settings, WHO recommends injectable artesunate for severe malaria. Although this is the most effective treatment for severe malaria and it can be administered rapidly and with ease, availability and uptake has been low. It is up to three times more expensive than traditionally used quinine. According to the UNITAID 2013 Medicines Market Landscape, less than 15% of the total volume of injectable artesunate needed to treat severe malaria was procured in 2012. This new UNITAID-supported project aims to increase access to injectable artesunate by promoting and supporting its use, helping new manufacturers to enter the market by attaining WHO approval and by preventing stock-outs and reducing product price by at least 20% by mid-2016.

In cases where a health facility is not within immediate reach of a severely sick child, WHO recommends the use of fast-acting pre-referral treatment with rectal artesunate. A community health worker or a mother can administer these suppositories, thereby buying time while the child is transported to a health facility for continued treatment. Access to this product is currently limited though: no WHO-approved rectal artesunate product is currently on the market.

This UNITAID- supported market intervention is led by the Medicines for Malaria Venture (MMV) and implemented by CHAI and the Malaria Consortium initially focusing on six countreis: Cameroon, Ethiopia, Kenya, Malawi, Nigeria and Uganda. MMV and partners aim to improve market conditions and show the feasibility of switching to injectable artesunate as well as to support manufacturers to gain WHO approval and enter the market for both injectable and rectal artesunate products.

ENDS

© Scoop Media

 
 
 
 
 
World Headlines

 

Gordon Campbell: On The French Election Result

Macron is shaping as the third major test case, after Bill Clinton, after Tony Blair – on whether the aim of ‘progressive social policy’ and realities of ‘neo-liberal economic settings’ can be made to credibly co-exist within the same sentence, let alone within the decrees from the Elysee Palace. More>>

Gordon Campbell: On The Snap Election In Britain

The election call is entirely opportunistic and self-serving and will – regardless of the outcome – put Britain in a worse negotiating position for managing its Brexit. More>>

Turkey: Observers Say Erdogan’s Constitutional Referendum Flawed

Lack of equal opportunities, one-sided media coverage and limitations on fundamental freedoms created unlevel playing field in Turkey’s constitutional referendum, international observers say. More>>

ALSO:

Westminster: NZ PM Condemns London Attack

“London is a place many thousands of New Zealanders have visited and called home, and where many more have friends and family based, so this attack feels very close to home,” Mr English says. More>>

ALSO:

Amnesty: Campaign Mass Hangings And Extermination At Syrian Prison

A chilling new report by Amnesty International exposes the Syrian government’s calculated campaign of extrajudicial executions by mass hangings at Saydnaya Prison. Between 2011 and 2015, every week and often twice a week, groups of up to 50 people ... More>>

Get More From Scoop

 
 
 
 
World
Search Scoop  
 
 
Powered by Vodafone
NZ independent news